Cyfuse is involved in multifaceted ventures based on its proprietary platform technology, and is working on the development of next-generation technologies with a focus on novel regenerative medicine and other products. Our goal is to get cellular products from Japan out into the world, build a system for delivering cellular products in a rational format to patients the world over, and create “new treatment options” for all patients who are afflicted with illness or injury.
The current corporate ethos of Cyfuse can be summed up as “to contribute to dramatic progress in therapy through the practical application of innovative Bio 3D Printing technology.”
In addition to the development of the pivotal Bio 3D Printing technology, future goals include greater partnership/collaboration with peripheral and support industries, such as those related to cell processing technology, evaluation techniques, automated cell processing, and robot technology, as well as the systemization of these technologies and the integration of the growing industries of the regenerative/cellular therapy markets.
Technology dissemination through Device Business
Drug development Support
Clinical applications in many tissue/organ.